Talazoparib
Pre-clinicalCompleted 3 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Aug 20, 2021 → Oct 11, 2021
NCT ID
NCT04987931About Talazoparib
Talazoparib is a pre-clinical stage product being developed by Pfizer for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04987931. Target conditions include Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05650476 | Pre-clinical | Active |
| NCT05288127 | Phase 2 | UNKNOWN |
| NCT05141708 | Pre-clinical | Completed |
| NCT03990896 | Phase 2 | Recruiting |
| NCT04987931 | Pre-clinical | Completed |
| NCT04635631 | Phase 1 | Completed |
| NCT03499353 | Phase 2 | Terminated |
| NCT03343054 | Phase 1 | Completed |
| NCT03148795 | Phase 2 | Completed |
| NCT02997163 | Phase 1 | Completed |
| NCT02921919 | Phase 2 | Completed |
| NCT03042910 | Phase 1 | Completed |
| NCT02997176 | Phase 1 | Completed |
| NCT03070548 | Phase 1 | Completed |
| NCT02034916 | Phase 2 | Terminated |
| NCT01286987 | Phase 1 | Completed |
Competing Products
20 competing products in Breast Cancer